MaxCyte is a commercial cell engineering company engaged on providing enabling platform technologies to improve cell-based research and development as well as cell therapeutic discovery, development and commercialization. Co.'s ExPERT platform, which is based on its Flow Electroporation technology, has been designed to address this cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes: three instruments, which Co. calls the ATx, STx and GTx. The MXCT stock yearly return is shown above.
The yearly return on the MXCT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MXCT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|